A Phase II Study of Alemtuzumab in Combination With CHOP [cyclophosphamide, doxorubicin, vincristine and prednisolone] as First-Line Treatment in Peripheral T-Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2009
At a glance
- Drugs Alemtuzumab; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 30 Jun 2009 Actual patient number (4) added as reported by ClinicalTrials.gov.
- 30 Jun 2009 Planned end date changed from May 2009 to Aug 2009 as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.